AIM: To evaluate the efficacy of rituximab combined with cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) in treating the initially diagnosed diffuse large B cell lymphoma (DLBL). METHODS: From Apr.20...AIM: To evaluate the efficacy of rituximab combined with cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) in treating the initially diagnosed diffuse large B cell lymphoma (DLBL). METHODS: From Apr.2002 to Feb. 2003, 52 patients were enrolled in this study. Chemotherapy was conducted with cyclophosphamide 600 mg·m^-2, vincristine 1.4 mg·m^-2,doorubicin 25mg·m^-2 on d 1 and prednisone 60 mg·d^-l for successive 5 d (standard CHOP). There were 6 courses, 3 wk each. Rituximab 375 mg·m^-2 was infused once a week, 2 d before the first course of chemotherapy (successive infusion) for 4 times on standard dose or for 6 times on extended dose. Or rituximab was infused once every 3 wk, 2 d before each CHOP (separated infusion) for 4 times on the schedule of standard dose or for 6 times on the extended dose. RESULTS: The complete response (CR) rate (60%) and total effective (100%) were achieved in 50 patients who were evaluated for efficacy, respectively. And among 34 patients in Ann Arbor stage Ⅲ and Ⅳ, 15 patients were completely relieved. The complete effective rate was 44%. Fifty patients were followed-up for (8±s 5) wk, 2-30wk and estimated progress free survival (PFS) rate of 16 wk was 87 %. Standard and extend regimen were not different in effect, as well as the separated or concentrated infusion of rituximab (P>0.05). The regimen could be well tolerated, and the major adverse reactions were infusion-related response (32 % ) and hematological toxicities (20 %). CONCLUSION:Rituximab in combined with CHOP can be successfully applied to the therapy of initially diagnosed diffuse large B cell lymphoma, with high CR rate and mild adverse reactions.展开更多
FOR those who want to tour the largest city in northeast China,September is a perfect time.On August 31.the 12th National Games opened in Shenyang.In addition to watching the games,visitors can explore the city,which ...FOR those who want to tour the largest city in northeast China,September is a perfect time.On August 31.the 12th National Games opened in Shenyang.In addition to watching the games,visitors can explore the city,which has a history spanning more than 2,000 years. Shenyang＇s history can be traced back as far as the Warring States Period（476 BC - 221 BC）.It＇s famous as the birthplace of the Qing Dynasty（1644-1911）,China＇s last dynasty.In 1625, Nurhachi,the first Qing emperor,established the capital in Shenyang,and changed its name to ＂Shengjing.＂ As a result,Shenyang houses one of China＇s two best-preserved imperial palace complexes and two emperor tombs.展开更多
文摘AIM: To evaluate the efficacy of rituximab combined with cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) in treating the initially diagnosed diffuse large B cell lymphoma (DLBL). METHODS: From Apr.2002 to Feb. 2003, 52 patients were enrolled in this study. Chemotherapy was conducted with cyclophosphamide 600 mg·m^-2, vincristine 1.4 mg·m^-2,doorubicin 25mg·m^-2 on d 1 and prednisone 60 mg·d^-l for successive 5 d (standard CHOP). There were 6 courses, 3 wk each. Rituximab 375 mg·m^-2 was infused once a week, 2 d before the first course of chemotherapy (successive infusion) for 4 times on standard dose or for 6 times on extended dose. Or rituximab was infused once every 3 wk, 2 d before each CHOP (separated infusion) for 4 times on the schedule of standard dose or for 6 times on the extended dose. RESULTS: The complete response (CR) rate (60%) and total effective (100%) were achieved in 50 patients who were evaluated for efficacy, respectively. And among 34 patients in Ann Arbor stage Ⅲ and Ⅳ, 15 patients were completely relieved. The complete effective rate was 44%. Fifty patients were followed-up for (8±s 5) wk, 2-30wk and estimated progress free survival (PFS) rate of 16 wk was 87 %. Standard and extend regimen were not different in effect, as well as the separated or concentrated infusion of rituximab (P>0.05). The regimen could be well tolerated, and the major adverse reactions were infusion-related response (32 % ) and hematological toxicities (20 %). CONCLUSION:Rituximab in combined with CHOP can be successfully applied to the therapy of initially diagnosed diffuse large B cell lymphoma, with high CR rate and mild adverse reactions.
文摘FOR those who want to tour the largest city in northeast China,September is a perfect time.On August 31.the 12th National Games opened in Shenyang.In addition to watching the games,visitors can explore the city,which has a history spanning more than 2,000 years. Shenyang＇s history can be traced back as far as the Warring States Period（476 BC - 221 BC）.It＇s famous as the birthplace of the Qing Dynasty（1644-1911）,China＇s last dynasty.In 1625, Nurhachi,the first Qing emperor,established the capital in Shenyang,and changed its name to ＂Shengjing.＂ As a result,Shenyang houses one of China＇s two best-preserved imperial palace complexes and two emperor tombs.
